4/30/2015 1 dr. anjum susan john, mrc. 4/30/20152 objectives what is informed consent ? the ethical...
TRANSCRIPT
04/18/23 2
Objectives Objectives • What is informed consent ?• The ethical justification of informed
consent • The informed consent process • The contents of the consent form• The documentation and filing of
consent forms
04/18/23 4
• Definition : It is the agreement of a prospective subject to participate in a study , reached after assimilation of all essential information related to the study.
• Which of the ethical principles does the informed consent justify?
04/18/23 6
1. It is a research2. Risks and benefits
3. Ask questions 4. Freedom to withdraw
participation
•Prospective consent + .consent in writing = Procedural issues
04/18/23 7
• Why should we take consent ?• Who provides consent ?• Who can solicit consent ?• When and where should consent be taken?• How should consent be taken ?• What is the effective period of informed consent ?• What should be the language used in consent
forms ?• Where should consent documents be kept?• What types of consent forms should be used for
different researches?
04/18/23 9
Consent must be provided by the prospective participant him/her self before the study has commenced
Exceptions 1.A child- parent/ legally authorized
representative2.A child able to comprehend things – assent
from child in writing 3.Participant advocate : 4.Consent for vulnerable populations-
prisoners, mentally challenged etc..,
04/18/23 10
Obtaining consent is the legal and ethical responsibility of the principal investigator.
FAQCan the co- investigator take consent ?Can study nurses or nurses who help in
routine clinical care take consent ?Can the responsibility for the consent be
delegated ?
04/18/23 11
Setting – where prospective participant can consider the request for participation as an autonomous individual
When – after giving adequate time for contemplating and asking questions
Except for emergency care protocols, consent must not be taken just before beginning a procedure or starting a therapeutic regimen
04/18/23 12
• A quiet room where the participant can take a voluntary decision with adequate time for consideration
• The research proposal must outline where and when consent would be obtained
• Inappropriate sites :• Crowded waiting room, public area or
operating room holding area etc..,
04/18/23 13
What is mentioned in the research proposal and consent form
Consent does not require to be resigned every year.
Consent must be re- obtained if :1. The consent document had been altered
/amended after the subject signed the document2. The subject was a minor at entry into the study
and has now reached the age of maturity3. The original consent document did not specify
the duration of the subject’s participation in the study.
04/18/23 14
• Simple understandable language addressing participant directly
• Language level understood by a grade 6-8 student
• Non English speaker : translate consent into his /her language
• Type of research modifies the process of consent
04/18/23 15
• Sealed signed informed consent forms along with their face sheets must be filed in the participant’s medical record files by the principal investigator
• Copies of signed informed consent form must be provided to the participant
• Copies of signed informed consent form must be kept in the research records of the principal investigator for 3 years after completion of the study
04/18/23 16
Recruitment of subjects Pre screening of prospective
subjects Consent process
Recruitment of subjects : protocols must mention how this is done
Prescreening :1.Check interest of prospective subject
2.Verify eligibility3.Assess feasibilityConsent process 1. In a quiet room2. Give information orally3. Give consent form to them , giving adequate time 4. Participants sign the document, if agree5. then investigator attests it
04/18/23 17
1. SIGNED INFORMED CONSENT2. WAIVER OF SIGNED INFORMED
CONSENT 3. WAIVER OF INFORMED CONSENT 4. GENETIC CONSENTS A, B, C and D
04/18/23 18
For prospective studies with more than minimal risk
(taken in triplicate)One- ParticipantOne- with PIOne in medical
record file of participant
Participant/guardian’s name
Sign, date signed
Child’s name
Sign and date signed
Witness name
Sign and date signed
PI’s name
Sign and date signed
04/18/23 19
Where research presents no more than minimal risk
of harm to the subject
1. Where the research involves no procedure for which written consent is normally required outside research context
2. Or , where the consent document would be the only identifiable link
3. Eg: Drawing of additional blood/body secretions during routine draw, questionnaires without participant identifiers, chart reviews preliminary to studies etc..,
04/18/23 20
Taken in duplicate
Signed by the principal investigator- means he is taking the responsibility for explaining the entire consent form and signing on behalf of the participant
One copy with the PIOne copy with the participantNo need to file a copy in the file of the
participant
04/18/23 21
• Waiver is provided by the RC to the principal investigator to allow him/her access to the participant’s medical record files
• The research cannot absolutely be carried out without the waiver.
• Collection/ study of existing data , documents, records, pathological specimens, or diagnostic specimens , if these sources are publicly available or if the information is recorded in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
04/18/23 23
• HGH WH RH AAH AKH ⃞� ⃞� ⃞� ⃞� ⃞�Others
•⃞�M R #: • PATIENTNAME:• DOB:• GENDER:• NATIONALITY:
04/18/23 24
You are free to ask as many questions as you like before, during or after in this research, should you decide to give consent to participate in this research study. ( AUTONOMY)
The information in this form is only meant to better inform you of all possible risks or benefits. ( AUTONOMY)
Your participation in this study is voluntary. You do not have to take part in this study, and your refusal to participate will involve no penalty or loss of rights to which you are entitled. (AUTONOMY)
You may withdraw from this study at any time without penalty or loss of rights or other benefits to which you are entitled. (AUTONOMY)
The investigator (s) may stop your participation in this study without your consent for reasons such as: it will be in your best interest; you do not follow the study plan; or you experience a study-related injury. ( ONLY SITUATIONS WHERE INVESTIGATOR MIGHT DECIDE FOR PARTICIPANTS)
04/18/23 25
• Project title:• Name of Principal Investigator:• Location and phone numbers:
[provide appropriate daytime contact information and after-hours or on weekends]
04/18/23 26
(A brief introduction is given about the research, what it hopes to achieve,
who is conducting it etc..,)
04/18/23 27
( Brief, clear description of the purpose, goals and objectives of the
research are provided here)
04/18/23 28
( A brief description on how research participants are selected, the inclusion
and exclusion criteria used to select the sample population and an
explanation of why this particular participant is being considered for
inclusion in the study)• APPLICATION OF PRINCIPLE OF JUSTICE
04/18/23 29
In case the prospective participant is to be recruited from the patient clientele of
treating physicians who also are investigators in the research a
description is given to the participant about what parts of the treatment
constitutes routine treatment and what constitutes research activities
PROVIDING ALL INFORMATION NEEDED TO TAKE AN INFORMED DECISION
04/18/23 30
(Brief, clear explanation of procedures involving the subject)
PROVIDING ALL INFORMATION NEEDED TO TAKE AN INFORMED DECISION
04/18/23 31
(Describe physiological, psychological and social factors of discomfort or
risks involved in the study
SO THAT THERE IS NO COERCION TO PARTICIPATE
04/18/23 33
(Brief description of any direct or indirect benefits to the subject).
APPLICATION OF THE PRINCIPLE OF BENEFICENCE
04/18/23 34
1. ( A description of all alternative procedures or treatment options
available to the potential research participant , so that the participant is
free to choose which treatment modality to adopt)
TO SHOW THAT THE INVESTIGATOR IS MAINTAINING EQUIPOISE BEFORE THE
STUDY
04/18/23 35
( A description is provided about whether the research treatment
would be available to the participant even after the study has
concluded)APPLICATION OF PRINCIPLE OF
BENEFICENCE
04/18/23 36
1. (In case of any types of injury or enquiry, provide name of
Supervisor and office phone number to contact at any time of
the day or night ).
2. PRINCIPLE OF AUTONOMY
04/18/23 37
1. ( Provide details of any compensation which might be
provided in lieu of their participation in the research).
2. APPLICATION OF PRINCIPLE OF BENEFICENCE
04/18/23 38
1. ( Describe how long the prospective participant is expected to be in the
research and what expectations the investigator might have about the
participant’s time spent in the research)
04/18/23 39
1. ( Give information to the participant about all the sponsors of the
research, any issues of conflict of interest and also where the
research will be conducted) PROVIDING ALL INFORMATION NEEDED
TO TAKE AN INFORMED DECISION
04/18/23 40
Describe steps to protect confidentiality of data and
anonymity of the participant information )
APPLICATION OF THE PRINCIPLE OF JUSTICE
04/18/23 41
( A statement that there is no pressure on the prospective subject to participate in the
study , that he/she is free to choose any of the treatment modalities offered and that there is no pressure on the participant to
continue in the study even after enrollment)
VOLUNTARINESS, PRINCIPLE OF AUTONOMY
04/18/23 42
1. ( An option is given to the potential participant to continue or withdraw
from the study even after enrollment in the research)
PRINCIPLE OF AUTONOMY, FREEDOM OF CHOICE
04/18/23 43
1. ( A description is given on when and how the study is expected to be
completed, what happens when the study is completed, whether the participant is further entitled to
contact the investigators after such time , whether the findings of the research will be revealed to them and if the results of the research would be applied to them or not)
04/18/23 44
1. ( Description of the instances in the study in which the investigator
might not provide all information needed to take an informed consent
at the outset of the study, why this is so and when there will be
debriefing if any of the undisclosed information to the participant )
04/18/23 45
• You (the participant) have read or have had read to you all of the above. Dr. Insert PI name or his/her authorized representative has provided you with a description of the study including an explanation of what this study is about, why it is being done, and the procedures involved. The risks, discomforts, and possible benefits of this research study, as well as alternative treatment choices, have been explained to you. You have the right to ask questions related to this study or your participation in this study at any time. Your rights as a research subject have been explained to you, and you voluntarily consent to participate in this research study. By signing this form, you willingly agree to participate in the research study described to you. You will receive a copy of this signed consent form. As long as the study is renewed as required by the IRB, your signature on this document is valid for the duration of the entire research study. Should any changes occur during the course of the study that may affect your willingness to participate, you will be notified.
04/18/23 46
• Research approved by the RC
• Research unapproved by the RC
• Accessing participant records or information without RC approval